Taken together, the results presented here showed that novel therapy design including MEK1 inhibitor (TAK-733) can be seriously considered in the future for the heavily pre-treated advanced breast cancers (e.g., TNBC and HER2+), while efficiencies may depend on different drug combinations and respective time and dose points. This evidence concerns the gene MAP2K1 and breast carcinoma.